Abstract
The understanding of the role of ‘neurohormones’ in the progression of heart failure has led to the utilization of agents that antagonize the activation of neurohormonal systems as effective therapy in patients with heart failure. As more evidence emerges linking proinflammatory cytokines to disease progression in heart failure, there is an increasing interest in developing anti-cytokine strategies that might be used as adjunctive therapy in patients with heart failure. Accordingly, the focus of the present review is to summarize the experimental and clinical studies that have attempted to modulate the effects of cytokines in heart failure. Strategies have been employed to either suppress cytokine production or to prevent their toxic effects by interfering with the binding of cytokines to their cognate receptors.
Similar content being viewed by others
tReferences
Bozkurt B, Kribbs S, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382–1391.
Kubota T, McTiernan CF, Frye CS, Slawson SE, Koretsky AP, Demetris AJ, Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ Res 1997;81:627–635.
Mann DL. Cytokines as mediators of disease progression in the failing heart. In: Hosenpud JD, Greenberg BH, ed. Congestive Heart Failure. Philadelphia: Lippincott Williams & Wilkins, 2000:213–232.
Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation 1995;92:1479–1486.
Torre-Amione G, Kapadia S, Benedict CR, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201–1206.
Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964–971.
MacGowan GA, Mann DL, Kormas RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997;79:1128–1131.
Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional signiÆcance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92: 1487–1493.
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704–711.
Oral H, Dorn GW, II, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem 1997;272:4836–4842.
Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotsi CC, Quintana PJE, Sabbadini RA. Tumor necrosis factor alphainduced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854–2865.
Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989;42:270–275.
Engelmann GL, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. J Biol Chem 1990;265:1531–1536.
Brakebusch C, Nophar Y, Kemper O, Engelmann H, Wallach D. Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J 1992;11:943–950.
Kapadia S, Torre-Amione G, Yokoyama T, Mann DL. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-α in vitro. Am J Physiol 1995;37:H517-H525.
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323–329.
Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992;90:693–698.
Kapadia S, Lee JR, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995;96: 1042–1052.
Kapadia S, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ Res 1997;81:187–195.
Zabel P, Schade FU, Schlaak M. Inhibition of Endogenous TNF Formation by Pentoxifylline. Immunbiol 1993;187:447–463.
Zabel P, Greinert U, Entzian P, Schlaak M. Effects of pentoxifylline on circulating cytokines (TNF and IL-6) in severe pulmonary tuberculosis. In: Fiers W, Buurman WA, ed. Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Basel: S. Karger, 1993:178–181.
Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, Chiurco J, Kasdan P, Ahlers CM, Ecto LT, Crumpacker CS. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acq Immun Defic Syndrome 1993;6:787–794.
Giroir BP, Beutler B. Effect of amrinone on tumor necrosis factor production in endotoxin shock. Circ Shock 1992;36:200–207.
Remick DG, Strieter RM, Lynch IJP, Nguyen D, Eskandari M, Kunkel SL. In vivo dynamics of murine tumor necrosis factor-α gene expression. Kinetics of dexamethasone-induced suppression. Lab Invest 1989;60:766–771.
Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, Black RA. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 1994;370:218–220.
Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994;380:555–557.
McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nicholas J, Pryzwansky M, Schoenen F, Sekut6L, Truesdale A, Vergheses M, Warner J, Ways JP. Regulation of tumor necrosis factor-α by a metalloproteinase inhibitor. Nature 1994;370:558–561.
Sampaio EP, Sarno EN, Galilly R, Cohen ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991;173:699–703.
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing messenger RNA degradation. J Exp Med 1993;177:1675–1680.
Parrillo JE, Cunnion RE, Epstein SE, Parker ME, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO, Alling D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS. A prospective randomized controlled tiral of prednisone for dilated cardiomyopathy. N Engl J Med 1989;321:1061–1068.
Sindhwani R, Yuen J, Hirsch H, Tegguy A, Galvao M, Levato P, LeJemtel TH. Reversal of low flow state attenuates immune activation in severe decompensated congestive heart failure. Circulation 1993;88: I-255.
Leier CV, Huss P, Lewis RP, Unverferth DV. Druginduced conditioning in congestive heart failure. Circulation 1982;65:1382–1387.
Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980; 100:622–630.
Milani RV, Mehra MR, Endres S, Eigler A, Cooper S, Lavie CJ Jr, Ventura HO. The clinical relevance of circulating tumor necrosis factor-α in acute decompensated chronic heart failure without cachexia. Chest 1996;110:992–997.
Deng MC, Erren M, Lutgen A, Zimmermann P, Brisse B, Schmitz W, Assman G, Breithardt G, Scheld HH. Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. Int J Cardiol. 1996;57: 129–134.
Wagner DR, Combes A, McTiernan CF, Sanders VJ, Lemster B, Feldman AM. Adenosine inhibits lipopolysacchide-induced cardiac expression of tumor necrosis factor-α. Circ Res 1998;82:47–56.
Wagner DR, McTiernan CF, Sanders VJ, Feldman AM. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-α in the failing human heart. Circulation 1998;97:521–524.
Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091–1093.
Meldrum DR, Cain BS, Cleveland JC Jr, Meng X, Ayala A, Banerjee A, Harken AH. Adenosine decreases post-ischemic cardiac TNFa production: anti-inflammatory implications for preconditioning and transplantation. Immunology 1997;92:472–477.
Mohler ER III, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, Cropp AB, Pressler ML. Role of cytokines in the mechanism of action of amlodipine: The PRAISE heart failure trial. J Am Coll Cardiol 1997;30:35–41.
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107–1114.
Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann D. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure. Circulation 1999;99:3224–3226.
Bozkurt B, Torre-Amione G, Soran OZ, Feldman AM, Blosch C, Warren M, Mann DL. Results of a phase I trial with tumor necrosis factor receptor (p75) fusion protein (Etanercept) in patients with heart failure. J Am Coll Cardiol 1999;33:2 Suppl I, 1110–10.
Bozkurt B, Torre-Amione G, Deswal A, Soran OZ, Whitmore J, Warren M, Mann DL. Regression of left ventricular remodeling in chronic heart failure after treatment with enbrel (Etanercept, p75 TNF receptor Fc fusion protein). Circulation 1999;100:I, 105.
Bozkurt B, Shan K, Seta Y, Oral H, Mann DL. Tumor necrosis factor-α and tumor necrosis factor receptors in human heart failure. Heart Fail Rev 1996; 1:211–219.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deswal, A., Misra, A. & Bozkurt, B. The Role of Anti-Cytokine Therapy in the Failing Heart . Heart Fail Rev 6, 143–151 (2001). https://doi.org/10.1023/A:1011462011567
Issue Date:
DOI: https://doi.org/10.1023/A:1011462011567